Lupin Will Pay $150M To End Glumetza Antitrust Suit

By Lauren Berg · September 20, 2021, 10:10 PM EDT

Direct buyers of blood sugar medication Glumetza on Monday inked a $150 million deal in California federal court with Lupin Pharmaceuticals, which is accused of taking part in a scheme to...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login